ReWalk Robotics Ltd. (RWLK) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Ori Gon - CFO Larry Jasinski - CEO Conference Call Participants Yoon-Seo Kang - H.C. Wainwright Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Q1 2021 ReWalk Robotics Limited Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ori Gon. Please go ahead. Ori Gon Thank you, Misty. G ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or For the transition period from _____ to ______ Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exact name of registrant as specified in charter) | Israel Not applicable | | | | --- | --- | --- ...

ReWalk Robotics Ltd. (RWLK) Q4 2020 Earnings Conference Call February 18, 2021 8:30 AM ET Company Participants Ori Gon - CFO Larry Jasinski - CEO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2020 ReWalk Robotics Earnings Conference Call. Please note that today's call is being recorded. [Operator Instructions] I would now like to hand the conference to our CFO, Ori Gon. Ori, the floor is yours. Ori Gon T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exact name of registrant as specified in charter) | Israel | Not applicable | | --- | --- | | (State or ...

ReWalk Robotics Ltd. (RWLK) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Ori Gon - Chief Financial Officer Larry Jasinski - Chief Executive Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2020 ReWalk Robotics LTD Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] I wou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exact name of registrant as specified in charter) | Israel | Not applicable | | --- | --- | | ...

ReWalk Robotics Ltd. (RWLK) Q2 2020 Earnings Conference Call August 12, 2020 8:30 AM ET Company Participants Ori Gon - Chief Financial Officer Larry Jasinski - Chief Executive Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter 2020 ReWalk Robotics Limited Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there’ll be a quest ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exact name of registrant as specified in charter) Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or | Israel | Not applicable | | --- | --- | | (Sta ...

Financial Data and Key Metrics Changes - The company's Q1 2020 revenue was $760,000, significantly impacted by the COVID-19 pandemic, with a gross margin of 49% compared to 59% in the prior year quarter [21][24]. - The net loss for Q1 2020 was $3.8 million, slightly improved from a net loss of $4 million in Q1 2019 [27]. - Operating expenses decreased by $500,000 or 11% compared to the prior year quarter, remaining flat compared to the previous quarter [24]. Business Line Data and Key Metrics Changes - Revenue from Personal 6.0 products totaled $714,000, while the Rehab ReStore device generated $46,000 [21]. - The company had 13 active SCI rentals and seven ReStore trials at the end of the quarter, representing a rental pipeline of $1.5 million in revenue [22]. Market Data and Key Metrics Changes - The total number of SCI pending insurance cases was 115 at the end of the quarter, with 98 in Germany and 17 in the U.S., a decrease from 145 at the end of 2018 [23]. - The company executed contracts with major German insurers covering over 20 million Germans, which is expected to enhance market access [15][31]. Company Strategy and Development Direction - The company is focusing on expanding telehealth capabilities and home therapy solutions in response to COVID-19, modifying agreements with Harvard's Biodesign laboratory [8][17]. - New distribution agreements for two product categories are set to begin in Q3 2020, aimed at enhancing revenue and clinic relationships [19][20]. Management's Comments on Operating Environment and Future Outlook - Management noted that the COVID-19 pandemic significantly affected business operations, particularly in sales processes requiring in-person contact [10]. - The company anticipates that insurance contracts in Germany will positively impact revenue as clinics reopen and users gain access for evaluations and training [12]. Other Important Information - The company has taken steps to ensure financial stability during the crisis, including workforce reductions and careful inventory management [14][25]. - A public hearing for the CMS application regarding a new HCPCS code is scheduled for June 1, which is crucial for reimbursement processes [9][35]. Q&A Session Summary Question: What does CMS need to do before providing reimbursement amounts? - The first step is issuing a temporary code, with a public hearing to discuss recommendations and comments from the company and clinicians [47][48]. Question: Have there been any product deliveries under the German insurance contracts post-COVID-19? - Yes, nearly all units placed from Q1 are under these contracts, with some patients receiving their units shortly after contract establishment [51][52]. Question: What is the status of the VA trial and any data publications? - The VA completed enrollment of 161 patients, with follow-up on approximately 125, but the timeline for data publication may be affected by COVID-19 [53][54]. Question: What synergies are expected from the new MediTouch products? - Both new product lines are expected to enhance clinic and home sales, targeting the same patient demographics as existing products [55][56].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exact name of registrant as specified in charter) Israel Not applicable (State or other jurisdict ...